Skip to main content
Dipesh Uprety, MD, Oncology, Detroit, MI

DipeshUpretyMD

Oncology Detroit, MI

Thoracic Cancer

Assistant Professor

Dr. Uprety is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Uprety's full profile

Already have an account?

  • Office

    4100 John R St
    Detroit, MI 48201
    Phone+1 313-576-8722

Education & Training

  • Gundersen Lutheran Medical Foundation
    Gundersen Lutheran Medical FoundationFellowship, Hematology and Medical Oncology, 2019
  • Abington Memorial Hospital
    Abington Memorial HospitalResidency, Internal Medicine, 2013 - 2016
  • B.P. Koirala Institute of Health Sciences
    B.P. Koirala Institute of Health SciencesClass of 2009

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2020 - 2026
  • MN State Medical License
    MN State Medical License 2019 - 2020
  • WI State Medical License
    WI State Medical License 2016 - 2019
  • PA State Medical License
    PA State Medical License 2013 - 2016
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • Deaths from Advanced Lung Cancer Have Dropped Significantly Since Immunotherapy Became Standard-of-Care
    Deaths from Advanced Lung Cancer Have Dropped Significantly Since Immunotherapy Became Standard-of-CareAugust 12th, 2024
  • Advanced Lung Cancer Deaths Drop with Immunotherapy
    Advanced Lung Cancer Deaths Drop with ImmunotherapyAugust 7th, 2024
  • The Largest Population-Based Study to Date Supports the Survival Benefits of Immunotherapy for People with Metastatic Non-Small Cell Lung Cancer
    The Largest Population-Based Study to Date Supports the Survival Benefits of Immunotherapy for People with Metastatic Non-Small Cell Lung CancerJuly 29th, 2024